AInvest Newsletter
Daily stocks & crypto headlines, free to your inbox
Ernexa Therapeutics will present data on its novel cell therapy platform at the 67th ASH Annual Meeting. The presentation, titled "Gene-modified iPSC-derived MSCs convert immunosuppressive tumor microenvironments (TMEs) into distinct Pro-inflammatory TMEs," will highlight the potential of the iMSC platform to transform the tumor microenvironment and drive a targeted immune response for the treatment of advanced cancer and autoimmune disease.
Daily stocks & crypto headlines, free to your inbox
Comments
No comments yet